New combo aims to wipe out lingering leukemia cells
NCT ID NCT04501939
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 35 times
Summary
This study tests whether adding cirmtuzumab to the standard drug venetoclax can eliminate remaining cancer cells in people with chronic lymphocytic leukemia (CLL). It involves 5 adults who still have detectable leukemia despite at least 12 months of venetoclax. The goal is to see if the combination can make the cancer undetectable after 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UCSD Koman Family Outpatient Pavilion
San Diego, California, 92037, United States
Conditions
Explore the condition pages connected to this study.